» Articles » PMID: 38758522

Cigarette Smoking and Prostate Cancer Aggressiveness Among African and European American Men

Overview
Specialties Oncology
Public Health
Date 2024 May 17
PMID 38758522
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Smoking is a modifiable lifestyle factor that has not been established as a prostate cancer risk factor, nor emphasized in prostate cancer prevention. Studies have shown that African American (AA) smokers have a poorer cancer prognosis than European Americans (EAs), while having a lower prevalence of heavy smoking. We examined the relationship between cigarette smoking and prostate cancer aggressiveness and assessed racial differences in smoking habits on the probability of high-aggressive prostate cancer.

Methods: Using data from the North Carolina-Louisiana Prostate Cancer Project (n = 1,279), prostate cancer aggressiveness was defined as high or low based on Gleason scores, serum prostate-specific antigen levels, and tumor stage. Cigarette smoking was categorized as current, former, or never smokers. Multivariable logistic regression was used to estimate adjusted odds ratios (OR) and 95% confidence intervals (CI).

Results: Self-reported current (OR = 1.99; 95% CI 1.30-3.06) smoking was associated with high-aggressive prostate cancer relative to never smokers. When stratified by self-reported race, the odds of having high-aggressive cancer increased among AA current (OR = 3.58; 95% CI 2.04-6.28) and former smokers (OR = 2.21; 95% CI 1.38-3.53) compared to AA never smokers, but the odds were diminished among the EA stratum (P = 0.003).

Conclusion: Cigarette smoking is associated with prostate cancer aggressiveness, a relationship modulated by self-reported race. Future research is needed to investigate types of cigarettes smoked and metabolic differences that may be contributing to the racial disparities observed.

Citing Articles

Impact of Smoking on Overall and Cancer-Specific Mortality in Prostate Cancer: Elevated Risks in Older and Early-Stage Patients-A Population-Based Study.

Lin R, Liu C, Huang S, Chiu A, Wu Y, Tseng W Life (Basel). 2024; 14(10).

PMID: 39459581 PMC: 11509152. DOI: 10.3390/life14101281.


Impacts of Interleukin-10 Promoter Genotypes on Prostate Cancer.

Chin Y, Tsai C, Ma H, Cheng D, Tsai C, Wang Y Life (Basel). 2024; 14(8).

PMID: 39202777 PMC: 11355935. DOI: 10.3390/life14081035.


Lifestyle medicine and prostate cancer: Time to look at the bigger picture?.

Gautam G Indian J Urol. 2024; 40(3):143-144.

PMID: 39100609 PMC: 11296589. DOI: 10.4103/iju.iju_226_24.

References
1.
Hickey K, Do K, Green A . Smoking and prostate cancer. Epidemiol Rev. 2001; 23(1):115-25. DOI: 10.1093/oxfordjournals.epirev.a000776. View

2.
Hussain F, Aziz H, Macchia R, Avitable M, Rotman M . High grade adenocarcinoma of prostate in smokers of ethnic minority groups and Caribbean Island immigrants. Int J Radiat Oncol Biol Phys. 1992; 24(3):451-61. DOI: 10.1016/0360-3016(92)91059-v. View

3.
Murphy A, Akereyeni F, Nyame Y, Guy M, Martin I, Hollowell C . Smoking and prostate cancer in a multi-ethnic cohort. Prostate. 2013; 73(14):1518-28. PMC: 3931574. DOI: 10.1002/pros.22699. View

4.
Al-Fayez S, El-Metwally A . Cigarette smoking and prostate cancer: A systematic review and meta-analysis of prospective cohort studies. Tob Induc Dis. 2023; 21:19. PMC: 9900478. DOI: 10.18332/tid/157231. View

5.
Cooke J . Angiogenesis and the role of the endothelial nicotinic acetylcholine receptor. Life Sci. 2007; 80(24-25):2347-51. PMC: 1941778. DOI: 10.1016/j.lfs.2007.01.061. View